RxDoctor Payments Data

Magdalena Espinoza, MD

Gastroenterology · Dallas, TXNPI 1205275260

Payments from drug & device makers

$58,539in general payments, 2019–2025

Across 119 payments — averaging $491.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GE HealthCare$57K
  • AbbVie$561
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$480
  • Takeda Pharmaceuticals U.S.A., Inc.$474
  • Braintree Laboratories, Inc.$100
  • Boston Scientific$56
  • plus $208 from 10 others

What the payments were for

  • Food & beverage$1,84998%
  • Education$312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$58,539 in reported general payments places this provider in the 85th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$60,099
Medicare patients
259
Services billed
446

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib15$112,210
CreonLipase/Protease/Amylase16$90,073
LinzessLinaclotide49$43,466
XifaxanRifaximin19$40,828
TrulancePlecanatide20$36,382
MotegrityPrucalopride Succinate23$27,407
Lubiprostone45$6,733
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates92$6,019
SutabSod Sulf/Pot Chloride/Mag Sulf22$3,905
Esomeprazole Magnesium49$3,011
Omeprazole164$2,711
Rabeprazole Sodium27$1,561
SuprepSodium, Potassium,mag Sulfates13$1,530
Dicyclomine Hcl23$551
Famotidine26$547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Creon, Linzess$561$245,74980 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$480$77,21039 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$474$27,40723 claims
Braintree Laboratories, Inc.Sutab$100$3,90522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →